Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

NarodowyInstytutu Onkologii im. Marii Sklodowskiej–Curie–Panstwowy Instytutu Badawczy

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of the Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, detailing its management, collaborations, patient studies, and pipeline products. It highlights various sponsored studies including TakeAim Lymphoma, Leukemia, and CLL, as well as the institute's financial information and governance structure. The content is structured to inform stakeholders about the institute's operations and research initiatives.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · clean, no other CRIS news in the window
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by Narodowy Instytut Onkologii?

The institute sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is the focus of the pipeline at Narodowy Instytut Onkologii?

The pipeline includes products like Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

Who is part of the management at Narodowy Instytut Onkologii?

The management includes a Board of Directors and various advisory boards.

What collaborations does Narodowy Instytut Onkologii engage in?

The institute engages in partner collaborations and scientific research collaborations.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Emavusertib
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →